Gypenosides (GP) are a type of
traditional Chinese medicine (TCM) extracted from plants and commonly applied for treatment of
metabolic diseases. This study aims to explore the effects of GP extracts on alleviating
non-alcoholic fatty liver disease (
NAFLD). In this experiment, C57BL/6 J mice were randomly assigned into normal diet control (ND), HFHC (high-fat and high-
cholesterol) and HFHC + GP (GP) groups. Mice in HFHC group were fed HFHC diet combined with
fructose drinking water for 12 weeks to induce the animal model of
NAFLD, followed by ordinary
drinking water until the end of the experiment. In the HFHC + GP group, mice were fed HFHC diet combined with
fructose drinking water for 12 weeks, followed by GP-containing
drinking water till the end. Mouse
body weight was measured weekly. After animal procedures, mouse liver and serum samples were collected. It is shown that GP administration reduced
body weight, enhanced the sensitivity to
insulin resistance (IR) and decreased serum levels of ALT, AST and TG in
NAFLD mice. In addition, GP treatment alleviated
steatohepatitis, and downregulated ACC1, PPARγ, CD36, APOC3 and
MTTP levels in mice fed with HFHC diet. Furthermore, GP treatment markedly improved intestinal microbiota, and reduced relative abundance ratio of Firmicutes / Bacteroidetes in the feces of
NAFLD mice. Our results suggested that GP alleviated
NAFLD in mice through improving intestinal microbiota.